Sweden
-
Novo Nordisk inks US$1.3B licensing agreement with Sweden’s Nanexa for long-acting injectables
The agreement comes as Novo continues to strengthen its position in cardiometabolic medicines, where longer dosing intervals are a growing focus of research and development.
-
Sobi strikes US$580M lacutamab deal with Innate Pharma for CTCL
The study is designed to provide confirmatory evidence for lacutamab in two CTCL subtypes, Sézary syndrome and mycosis fungoides, potentially supporting full regulatory approval.
-
Gesynta Pharma starts Phase 2 trial for novel endometriosis treatment
Researchers plan to enroll approximately 190 women aged 18 to 45 across seven European countries, including the UK, Italy, Poland, Romania, Bulgaria, the Czech Republic, and Hungary.
-
Lonza completes CDMO pivot with USD3B sale of capsule business to Lone Star
The company also secured additional preferential participation in future exit proceeds, though these returns depend on Lone Star first recovering its initial equity investment.
-
Nanologica acquires Ardena’s Syntagon Facility to expand API manufacturing
The site will continue operating as a subsidiary under the Syntagon name, maintaining its established brand presence in the pharmaceutical manufacturing sector.